GILD

Dernières nouvelles pour Gilead Sciences (NASDAQ:GILD) Stock

Gilead Sciences

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Gilead Sciences Inc

GILEAD SCIENCES ORD

Gildan Activewear, Inc. Class A Sub. Vot. Common Stock

Gildan Activewear Inc

JP Morgan analyst Chris Schott maintains Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Overweight and raises the price target from $95 to $100.

News

Price Target

Analyst Ratings

JP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $100

The U.S. Department of Health and Human Services (HHS), through the Centers for Medicare &amp; Medicaid Services (CMS), has released a Request for Information (RFI) regarding a new initiative to lower prescription drug costs for Medicare recipients.
The Medicare $2 Drug List Model, developed under President Biden&#8217;s Executive Order 14087, seeks to offer certain generic drugs for a fixed copayment of no more than $2 per month.
This initiative targets commonly prescribed drugs for conditions like high cholesterol and high blood pressure.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40534249/novo-nordisks-ozempic-might-be-among-2027-medicare-price-negotiation-targets" rel="noreferrer noopener">Novo Nordisk&#8217;s Ozempic Might Be Among 2027 Medicare Price Negotiation Targets</a>.
The Center for Medicare and Medicaid Innovation (Innovation Center) has designed the Medicare $2 Drug List Model to test whether simplifying access to affordable, clinically important generics will improve health outcomes, improve medication adherence, and boost overall satisfaction with the Medicare Part D program.
These drugs, which would not be subject to typical utilization management requirements, could be available at all participating pharmacies as early as January 2027.
The initial list of <a target="_blank" href="https://www.cms.gov/newsroom/press-releases/biden-harris-administration-takes-next-step-proposed-model-lower-prescription-drug-costs-people" rel="noreferrer noopener">drugs</a> for the $2 Drug List Model has been carefully developed through a rigorous process. It incorporates input from physicians, pharmacists, and health policy experts to ensure that the selected medications address common conditions for Medicare recipients.
The concept of a fixed-cost drug list is not new, with many retail pharmacies already offering generic medications at low, standardized prices.
However, the Medicare $2 Drug List Model will be tailored specifically to Medicare recipients.
Last week,&nbsp;the HHS released final guidance for the second &nbsp;Medicare Drug Price <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">Negotiation Program cycle</a>.
This initiative&nbsp;<a target="_blank" href="https://www.cms.gov/newsroom/press-releases/hhs-releases-final-guidance-second-cycle-historic-medicare-drug-price-negotiation-program" rel="noreferrer noopener">aims</a> to provide lower drug prices starting in 2026 and 2027.
The first round of negotiations focused on ten specific drugs. When the new prices take effect in 2026, Medicare recipients should save approximately $1.5 billion in <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41166018/medicare-drug-price-negotiation-program-gets-final-guidance-for-second-cycle-1-5b-savings-expecte" rel="noreferrer noopener">out-of-pocket costs</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41256266/is-the-iphone-losing-its-buzz-among-teens-piper-sandler-finds-out" target="_blank" rel="noreferrer noopener">Is The iPhone Losing Its Buzz Among Teens? Piper Sandler Finds Out</a></li>
</ul>
Image via Shutterstock

Biotech

Government

Health Care

General

AMGN

BMRN

REGN

VRTX

Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients

– Latest Outcomes From HIV Prevention and Treatment Clinical Research, Including Data From Pivotal Phase 3 PURPOSE 1 &amp; 2 Trials –
– Real World Evidence in COVID-19 Reinforce Veklury (remdesivir) as the Antiviral Standard of Care for the Treatment of People Hospitalized for COVID-19 –
– Investigational Obeldesivir Safety and Tolerability Data From BIRCH and OAKTREE Trials Support Continued Evaluation as a Potential Treatment Option for RSV –
Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) today announced the upcoming presentation of new findings from its antiviral research and development programs at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fidweek.org%2F&amp;esheet=54133570&amp;newsitemid=20241008521376&amp;lan=en-US&amp;anchor=IDWeek+2024&amp;index=1&amp;md5=101ec759acb70e35b111d17d3bfbcb58">IDWeek 2024</a>, taking place from October 16-19. The data from 31 presentations across HIV treatment and prevention, COVID-19 and viral hepatitis include one late breaker abstract and six oral presentations, reflecting Gilead's commitment to helping address the evolving needs of a diverse range of people and communities affected by some of the world's most challenging viruses.

Gilead To Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline And HIV Leadership At IDWeek 2024

Barclays analyst Carter Gould maintains Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Equal-Weight and raises the price target from $76 to $84.

Barclays Maintains Equal-Weight on Gilead Sciences, Raises Price Target to $84

Wells Fargo analyst Mohit Bansal upgrades Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) from Equal-Weight to Overweight and raises the price target from $78 to $100.

Upgrades

Wells Fargo Upgrades Gilead Sciences to Overweight, Raises Price Target to $100

Plans Regulatory Filings For Lenacapavir As PrEP By End Of 2024; Expanding Access In High-Incidence, Resource-Limited Countries

Gilead Presents PURPOSE 2 Trial Data At HIVR4P Conference Showing Twice-Yearly Lenacapavir Reduced HIV Infections By 96% Among Cisgender Men And Gender-Diverse People

Goldman Sachs upgraded its 12-month price target for the S&amp;P 500 index from 5,600 to 6,300, driven by stronger-than-expected corporate earnings heading into the third quarter and robust demand <a href="https://www.benzinga.com/topic/artificial-intelligence">for artificial intelligence technologies. </a>
The revision, outlined in a report led by U.S. equity strategist David Kostin, reflects optimism around earnings-per-share (EPS) growth and margin expansion, particularly in key sectors like technology and healthcare.
The S&amp;P 500, which tracks the largest 500 U.S. corporations through the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), is currently trading less than 1% below its all-time high.
<h3 class="wp-block-heading">S&amp;P 500 Earnings Forecasts Upwardly Revised</h3>
Goldman Sachs now projects the S&amp;P 500&#8217;s earnings per share to rise to $268 in 2025, representing an 11% year-over-year increase. 
&#8220;The primary driver of the upward revision to our 2025 EPS estimate is greater margin expansion,&#8221; analysts wrote. 
This is up from the bank&#8217;s previous estimate of $256, which forecasted just 6% growth. For 2026, the investment bank forecasts further EPS growth to $288, or 7%, continuing a healthy upward trajectory.
For the current year, Goldman Sachs maintains its full-year EPS forecast of $241 for the S&amp;P 500, reflecting an 8% year-over-year growth, consistent with prior guidance.
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Year</th>
<th>Goldman Sachs&#8217; S&amp;P 500 EPS Forecast</th>
<th>Growth Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>2024</td>
<td>$241</td>
<td>+8%</td>
</tr>
<tr>
<td>2025</td>
<td>$268</td>
<td>+11%</td>
</tr>
<tr>
<td>2026</td>
<td>$288</td>
<td>+7%</td>
</tr>
</tbody>
</table>
</figure>
Goldman Sachs' earnings forecasts are supported by steady macroeconomic growth expectations. 
The firm's economists predict that U.S. GDP will grow by 2.3% in 2025, followed by a 2.0% expansion in 2026. 
Despite inflationary pressures, the bank expects companies to maintain pricing power, which should help them offset rising labor and input costs.
<h3 class="wp-block-heading">AI and Semiconductor Recovery Boost IT Sector Outlook</h3>
A key driver behind Goldman Sachs' more bullish outlook is the increasing role of AI and the recovery in the semiconductor sector. 
According to the report, semiconductor shipments—excluding memory chips—are currently about 10% below their historical trend. 
As this shortfall reverses, the firm anticipates stronger margins for the industry, contributing approximately $7, or 20%, of the S&amp;P 500&#8217;s EPS growth in 2025.
The investment bank also highlighted the ongoing strength in mega-cap tech firms, such as Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Microsoft Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NYSE">MSFT</a>), Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), and Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>).
These companies have consistently delivered quarterly earnings surprises, with an average beat of 9% over the past four quarters.
Goldman Sachs noted that &#8220;while the magnitude of beats may moderate,&#8221; there is &#8220;strong ongoing AI demand that should benefit these stocks.&#8221;
<h3 class="wp-block-heading">Margin Expansion To Power 2025 Gains</h3>
Goldman Sachs has revised its expectations for S&amp;P 500 net margin expansion in 2025, now forecasting a 78 basis point increase compared to its earlier estimate of just 24 basis points. This enhanced margin outlook stems largely from a more favorable macroeconomic environment, where input costs are expected to rise at a slower pace than the prices charged by companies, thus widening margins.
One key factor behind the forecasted margin gains is the normalization of certain one-off expenses that have weighed heavily on corporate earnings in 2024. 
For instance, in the healthcare sector, companies like Bristol-Myers Squibb Co.(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), and Vertex Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) were significantly impacted by high R&amp;D-related charges earlier in the year. 
Goldman Sachs predicts these expenses will moderate in 2025, leading to an $83 boost in healthcare margins alone, contributing to a broader EPS uplift.
<h3 class="wp-block-heading">Downside, Upside Scenarios And Short-Term Targets</h3>
If economic growth slows more than expected, the S&amp;P 500's price-to-earnings (P/E) ratio could compress to 18x, which would imply a price target of 5,400—about 6% lower than current levels. Additionally, uncertainty surrounding U.S. monetary policy and the outcome of the 2024 election could lead to increased market volatility.
On the upside, if the P/E ratio remains stable at 22x, the index could climb to 6,600 in the next 12 months. In a more optimistic scenario, where economic growth remains robust and investor sentiment improves, Goldman Sachs suggests the P/E ratio could rise to 23x, pushing the S&amp;P 500 to 6,900 by year-end 2025.
For the remainder of 2024, Goldman Sachs expects the S&amp;P 500 to experience some volatility as investors weigh the implications of the Federal Reserve&#8217;s policy stance and the upcoming presidential election. 
The bank sees limited downside risks and has set a three-month price target of 6,000 for the index, up from a previous target of 5,600. Over the next six months, Goldman expects the index to reach 6,100.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/10/41191633/us-energy-stocks-notch-biggest-weekly-gains-in-2-years-exxon-hits-record-highs-as">US Energy Stocks Notch Biggest Weekly Gains In 2 Years, Exxon Hits Record Highs As Crude Surges To $75 On Israel-Iran Jitters</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Equities

Large Cap

Broad U.S. Equity ETFs

Tech

ETFs

AAPL

GOOG

GOOGL

MSFT

NVDA

S&P 500 Could Reach 6,300 In 12 Months, Says Goldman Sachs, Driven By 'Strong AI Demand' And 'Margin Expansion'

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)</h3>
<ul>
<li>Dividend Yield: 3.64%</li>
<li>RBC Capital analyst Brian Abrahams maintained a Sector Perform rating and raised the price target from $74 to $75 on Oct. 4. This analyst has an accuracy rate of 61%.</li>
<li>Needham analyst Joseph Stringer reiterated a Hold rating on Aug. 15. This analyst has an accuracy rate of 76%.</li>
<li>Recent News: On Oct. 2, Dr. Reddy&#8217;s signed voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100724&amp;t=be2bearmibe3na1">latest GILD news</a>.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100724&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="903" height="841" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/07071249/image-31.png" alt="" class="wp-image-583132" style="width:669px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/07071249/image-31.png 903w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/07071249/image-31-300x279.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/07071249/image-31-768x715.png 768w" sizes="(max-width: 903px) 100vw, 903px" /></a></figure>
<h3 class="wp-block-heading">GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>)</h3>
<ul>
<li>Dividend Yield: 3.94%</li>
<li>Jefferies analyst Peter Welford maintained a Buy rating and raised the price target from $52.5 to $53 on July 2. This analyst has an accuracy rate of 68%.</li>
<li>Guggenheim analyst Seamus Fernandez upgraded the stock from Neutral to Buy on March 4. This analyst has an accuracy rate of 62%</li>
<li>Recent News: The U.S. government has granted $72 million to European pharma giants GSK Plc, Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) and Australian firm CSL Limited (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CSLLY#OTC">CSLLY</a>) to more than double the U.S. supply of bird flu vaccines.</li>
<li>Benzinga Pro's real-time newsfeed <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100724&amp;t=be2bearmibe3na1">alerted to latest GSK news.</a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100724&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="888" height="856" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/07071336/image-32.png" alt="" class="wp-image-583133" style="width:706px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/07071336/image-32.png 888w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/07071336/image-32-300x289.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/07071336/image-32-768x740.png 768w" sizes="(max-width: 888px) 100vw, 888px" /></a></figure>
<h3 class="wp-block-heading">AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)</h3>
<ul>
<li>Dividend Yield: 3.19%</li>
<li>Morgan Stanley analyst Terence Flynn maintained an Overweight rating and boosted the price target from $211 to $218 on Aug. 12. This analyst has an accuracy rate of 70%.</li>
<li>Wells Fargo analyst Mohit Bansal maintained an Overweight rating and raised the price target from $200 to $205 on July 26. This analyst has an accuracy rate of 75%.</li>
<li>Recent News: AbbVie will announce its third-quarter financial results on Wednesday, Oct. 30, before the opening bell.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100724&amp;t=be2bearmibe3na1">ABBV stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100724&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="917" height="847" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/07071549/image-33.png" alt="" class="wp-image-583140" style="width:686px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/07071549/image-33.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/07071549/image-33-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/07071549/image-33-768x709.png 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/10/41194621/top-3-risk-off-stocks-that-may-explode-this-month">Top 3 Risk Off Stocks That May Explode This Month</a></li>
</ul>

Dividends

Pre-Market Outlook

Markets

Trading Ideas

ABBV

CSLLY

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) underwent analysis by 11 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $77.91, along with a high estimate of $95.00 and a low estimate of $70.00. This current average has increased by 2.65% from the previous average price target of $75.90. 
<img src="https://www.benzinga.com/files/images/story/2024/1728054144_0_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Gilead Sciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$75.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Joseph Catanzaro</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$95.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$74.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Robyn Karnauskas</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$83.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$72.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$85.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$70.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Steven Seedhouse</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$93.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Gilead Sciences. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Gilead Sciences compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Gilead Sciences's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Gilead Sciences's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/GILD/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Gilead Sciences analyst ratings.</a>
<h2>All You Need to Know About Gilead Sciences</h2>
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
<h3>Gilead Sciences's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Gilead Sciences displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 5.36%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 23.21%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Gilead Sciences's ROE excels beyond industry benchmarks, reaching 9.01%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.94%, the company showcases effective utilization of assets.
Debt Management: Gilead Sciences's debt-to-equity ratio is below the industry average. With a ratio of 1.28, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Peeling Back The Layers: Exploring Gilead Sciences Through Analyst Insights

RBC Capital analyst Brian Abrahams maintains Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Sector Perform and raises the price target from $74 to $75.

RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $75

Global

Gilead Donates Remdesivir For Emergency Use In Response To Marburg Virus Disease In Rwanda; Says It Will Donate Approximately 5,000 Vials Of Remdesivir To Rwanda Medical Supply

Dr. Reddy&#39;s Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:<a href="https://www.benzinga.com/stock/RDY#NYSE">RDY</a>, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as &quot;Dr. Reddy&#39;s&quot;)), today announced that it has entered into a royalty-free non-exclusive voluntary licensing agreement with Gilead Sciences Ireland UC for the manufacture and commercialisation of the drug, Lenacapavir, in India and 120 other countries.
Lenacapavir is a United States Food and Drug Administration (USFDA) approved drug indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations. Additionally, Lenacapavir is currently under investigation for the prevention of HIV (PrEP) which is yet to be approved globally.
Gilead Sciences first launched Lenacapavir under the brand name Sunlenca&reg; in the United States and Europe markets in the year 2022. It is a first-in-class HIV-1 capsid inhibitor.
Dr. Reddy&#39;s has been granted a non-exclusive voluntary licence to manufacture Lenacapavir and market it in 120 countries, for the current approved indication of HIV treatment in heavily treatment-experienced (HTE) adults with multi-drug resistant HIV. Dr. Reddy&#39;s will be responsible for technology transfer at its manufacturing site, conducting bioequivalence/clinical studies, product registration and launch in the agreed markets. Additionally, the agreement grants licence to Dr. Reddy&#39;s to manufacture and commercialise lenacapavir for the indication of prevention of HIV (PrEP) in 120 countries, if approved.

Dr. Reddy's Signs Voluntary Licensing Agreement With Gilead Sciences To Manufacture And Commercialise Lenacapavir In India And Other Countries

– License for Companies to Manufacture and Supply High-Quality, Low-Cost Versions of Lenacapavir for 120 Primarily Low- and Lower-Middle Income Countries –
– Gilead Plans to Price Product at No Profit to the Company and Supply Lenacapavir Until Generic Manufacturers Fully Support Demand –
– Agreements Also Cover Lenacapavir for HIV Treatment in Heavily Treatment-Experienced Adults with Multi-Drug Resistant HIV –
Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) today announced that it has signed non-exclusive, royalty-free <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gilead.com%2F-%2Fmedia%2Fgileadcorpredesign%2Fpdf%2FOther%2FLEN-VL.pdf&amp;esheet=54130468&amp;newsitemid=20241001289353&amp;lan=en-US&amp;anchor=voluntary+licensing+agreements&amp;index=1&amp;md5=3b86426aff5e7b0f39d036eaa6389b86">voluntary licensing agreements</a> with six pharmaceutical manufacturers to make and sell generic lenacapavir, subject to required regulatory approvals, in 120 high-incidence, resource-limited countries, which are primarily low- and lower-middle income countries. The agreements were signed in advance of any global regulatory submissions to enable these countries to quickly introduce generic versions of lenacapavir for HIV prevention, if approved.
The agreements advance Gilead's strategy to enable broad, sustainable access to lenacapavir for pre-exposure prophylaxis (PrEP) globally if it is approved, and align with Gilead's vision of ending the HIV epidemic for everyone, everywhere. Gilead will support low-cost access to the drug in high-incidence, resource-limited countries through a two-part strategy: establishing a robust voluntary licensing program, and planning to provide Gilead-supplied product at no profit to Gilead until generic manufacturers are able to fully support demand. Additionally, the agreements cover not only lenacapavir for HIV prevention (pending approval), but also lenacapavir for HIV treatment in heavily treatment-experienced (HTE) adults with multi-drug resistant HIV.

Gilead Signs Royalty-Free Voluntary Licensing Agreements With 6 Generic Manufacturers To Increase Access To Lenacapavir For HIV Prevention In Resource-Limited Countries

Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) has outperformed the market over the past 20 years by 3.1% on an annualized basis producing an average annual return of 11.54%. Currently, Gilead Sciences has a market capitalization of $104.43 billion. 
Buying $1000 In GILD: If an investor had bought $1000 of GILD stock 20 years ago, it would be worth $8,831.14 today based on a price of $83.88 for GILD at the time of writing.
<h3>Gilead Sciences's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727818474_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 20 Years Ago Would Be Worth $8,800 Today

As of Sept. 24, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Doximity Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>)</h3>
<ul>
<li>On Aug. 8, Doximity reported better-than-expected first-quarter financial results. Additionally, the company issued FY24 revenue guidance above estimates. "We were pleased to deliver strong profits and record engagement last quarter, as we beat on both our top and bottom lines," said Jeff Tangney, co-founder and CEO of Doximity. "Last quarter, a record 590,000 unique providers used our AI, telehealth, messaging, and scheduling workflow tools to save time and better serve their patients." The company's stock gained around 13% over the past month and has a <a href="https://www.benzinga.com/quote/DOCS">52-week high of $41.69</a>.</li>
<li>RSI Value: 82.05&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>DOCS Price Action: Shares of Doximity gained 1.4% to close at $41.50 on Monday.</li>
</ul>
<h3 class="wp-block-heading">Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)</h3>
<ul>
<li>Gilead Sciences voluntarily recalled one lot of its COVID-19 treatment, Veklury (remdesivir), for Injection 100 mg/vial, after discovering glass particles in the vials. The company's stock gained around 9% over the past month and &lt;a href=&#8221;https://www.benzinga.com/quote/GILD&#8221;&gt;&lt;em&gt; has a 52-week high &lt;/em&gt;&lt;/a&gt; of $87.86.</li>
<li>RSI Value: 72.77</li>
<li>GILD Price Action: Shares of Gilead Sciences rose 0.1% to close at $83.99 on Monday.</li>
</ul>
<h3 class="wp-block-heading">Genfit SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNFT#NASDAQ">GNFT</a>)</h3>
<ul>
<li>On Sept. 19, Genfit posted H1 2024 adjusted EPS of €0.53 and revenues and other income of €61.199 million. The company's stock gained around 15% over the past five days and has a <a href="https://www.benzinga.com/quote/GNFT">52-week high</a> of $6.05.</li>
<li>RSI Value: 70.41</li>
<li>GNFT Price Action: Shares of Genfit rose 3.1% to close at $4.99 on Monday.</li>
</ul>
<h3 class="wp-block-heading">Bullfrog AI Holdings, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRG#NASDAQ">BFRG</a>)</h3>
<ul>
<li>On July 25, BullFrog AI announced significant advancements in its ongoing collaboration with the Lieber Institute for Brain Development for specific molecular pathways associated with bipolar disorder, enabling the identification of new candidate drug targets. The company's stock has a 52-week high is $8.35.</li>
<li>RSI Value: 78.66</li>
<li>BFRG Price Action: Shares of Bullfrog AI gained 32.4% to close at $3.19 on Monday. </li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/40991631/jim-cramer-says-this-utilities-stock-is-a-buy-we-need-cheap-power">Jim Cramer Says This Utilities Stock Is A Buy: &#8216;We Need Cheap Power&#8217;</a></li>
</ul>

Short Ideas

BFRG

DOCS

GNFT

Top 4 Health Care Stocks That May Keep You Up At Night

Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) has voluntarily recalled one lot of its COVID-19 treatment, Veklury (remdesivir), for Injection 100 mg/vial, after discovering glass particles in the vials.
The company received a customer complaint that prompted an investigation, confirming the presence of foreign material in the product.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40840139/gilead-unveils-remarkable-outcomes-from-late-stage-lenacapavir-study-showing-promise-in-preventin" rel="noreferrer noopener">Gilead Unveils &#8216;Remarkable Outcomes&#8217; From Late-Stage Lenacapavir Study Showing Promise In Preventing HIV Infections</a>.
The <a target="_blank" href="https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/gilead-issues-voluntary-nationwide-recall-one-lot-veklury-remdesivir-injection-100-mgvial-due" rel="noreferrer noopener">affected</a> product is identified as Veklury lot # 47035CFA, distributed nationwide starting July 16, 2024. Gilead is notifying distributors and customers through UPS next-day air mail, instructing pharmacies to cease use of the affected lot and return any remaining vials.
Gilead is taking necessary measures to ensure the safety of patients and healthcare providers by facilitating the recall process.
The administration of a contaminated injectable could lead to health risks, including local irritation or swelling. If glass particles travel through the bloodstream, they may obstruct blood vessels in vital organs, potentially resulting in strokes or even death.
Gilead has reported no adverse events associated with this recall to date.
Veklury is designed for the treatment of COVID-19 in both adults and pediatric patients, specifically those who are hospitalized or non-hospitalized but at high risk of progression to severe COVID-19.
Its use is restricted to healthcare settings that manage severe reactions, including anaphylaxis.
In 2021, Gilead Sciences issued a nationwide recall of two lots of its COVID-19 treatment drug Remdesivir because they <a target="_blank" href="https://www.benzinga.com/general/biotech/21/12/24452924/gilead-recalls-two-lots-of-remdesivir-due-to-presence-of-glass-particulates" rel="noreferrer noopener">contained glass particulates</a>.
In the second quarter of 2024, Veklury&nbsp;sales decreased 16% year over year to $214 million, primarily due to lower rates of <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40291958/analysts-cite-improved-investor-sentiment-for-gilead-but-warn-of-limited-growth-at-" rel="noreferrer noopener">COVID-19-related hospitalizations</a>.
Price Action: GILD stock is down 0.05% at $83.90 at last check Monday.
Image via Unsplash
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40986953/novo-nordisk-ceo-to-face-senate-scrutiny-over-high-ozempic-and-wegovy-prices-hearing-scheduled-on" target="_blank" rel="noreferrer noopener">Novo Nordisk CEO To Face Senate Scrutiny Over High Ozempic And Wegovy Prices, Hearing Scheduled On Tuesday</a>.</li>
</ul>

Gilead Sciences Recalls One Lot Of Its COVID-19 Treatment Due To Presence Of Glass Particles

<a href="https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/gilead-issues-voluntary-nationwide-recall-one-lot-veklury-remdesivir-injection-100-mgvial-due">https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/gilead-issues-voluntary-nationwide-recall-one-lot-veklury-remdesivir-injection-100-mgvial-due</a>
Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) today announced it is issuing a voluntary recall of one lot of Veklury&#xAE; (remdesivir) for Injection 100 mg/vial, to the consumer level. Gilead received a customer complaint and confirmed the presence of a glass particle in the vial during the company's investigation.
Risk Statement: The administration of an injectable product that contains glass particles may result in local irritation or swelling in response to the foreign material. The glass particulate can potentially travel, through the blood vessels, to various organs and block blood vessels in the heart, lungs or brain which can cause stroke and even lead to death. To date, Gilead has not received any reports of adverse events related to this recall.
Veklury&#xAE; (remdesivir) for Injection 100 mg/vial is indicated for the treatment of COVID-19 in adults and pediatric patients (birth to less than 18 years of age weighing at least 1.5 kg) who are:
<ul>
<li>Hospitalized, or</li>
<li>Not hospitalized and have mild-to-moderate COVID-19 and are at high risk for progression to severe COVID-19, including hospitalization or death</li>
</ul>
Veklury&#xAE; (remdesivir) for Injection 100 mg/vial may only be administered in settings in which healthcare providers have immediate access to medications to treat a severe infusion or hypersensitivity reaction, such as anaphylaxis, and the ability to activate the emergency medical system (EMS), as necessary.

FDA Says Gilead Issues Voluntary Nationwide Recall Of One Lot Of Veklury For Injection 100 mg/Vial Due To The Presence Of A Glass Particle

High-rolling investors have positioned themselves bearish on Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in GILD often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 9 options trades for Gilead Sciences. This is not a typical pattern.
The sentiment among these major traders is split, with 22% bullish and 55% bearish. Among all the options we identified, there was one put, amounting to $35,055, and 8 calls, totaling $278,552.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $75.0 to $87.5 for Gilead Sciences during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Gilead Sciences stands at 445.5, with a total volume reaching 2,234.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Gilead Sciences, situated within the strike price corridor from $75.0 to $87.5, throughout the last 30 days.
<h3>Gilead Sciences Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726857586_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$8.9</td>
<td>$8.8</td>
<td>$8.8</td>
<td>$75.00</td>
<td>$41.2K</td>
<td style="text-align: right;">867</td>
<td style="text-align: right;">61</td>
</tr>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$8.85</td>
<td>$8.75</td>
<td>$8.73</td>
<td>$75.00</td>
<td>$38.4K</td>
<td style="text-align: right;">867</td>
<td style="text-align: right;">343</td>
</tr>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$9.45</td>
<td>$8.8</td>
<td>$8.83</td>
<td>$75.00</td>
<td>$36.1K</td>
<td style="text-align: right;">867</td>
<td style="text-align: right;">141</td>
</tr>
<tr>
<td>GILD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$6.25</td>
<td>$6.15</td>
<td>$6.15</td>
<td>$87.50</td>
<td>$35.0K</td>
<td style="text-align: right;">24</td>
<td style="text-align: right;">58</td>
</tr>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$8.75</td>
<td>$8.6</td>
<td>$8.6</td>
<td>$75.00</td>
<td>$34.3K</td>
<td style="text-align: right;">867</td>
<td style="text-align: right;">506</td>
</tr>
</tbody>
</table>

<h3>About Gilead Sciences</h3>
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
After a thorough review of the options trading surrounding Gilead Sciences, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Gilead Sciences's Current Market Status</h3>
<ul>
<li>Trading volume stands at 7,413,669, with GILD's price down by -0.71%, positioned at $83.31.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 48 days.</li>
</ul>
<h3>What The Experts Say On Gilead Sciences</h3>
4 market experts have recently issued ratings for this stock, with a consensus target price of $77.25.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Sector Perform rating on Gilead Sciences with a target price of $74. 
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Neutral with a new price target of $70. 
&#x2A; An analyst from Piper Sandler has decided to maintain their Overweight rating on Gilead Sciences, which currently sits at a price target of $95. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Neutral, adjusting the price target to $70. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Gilead Sciences options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Gilead Sciences Unusual Options Activity For September 20

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)</h3>
Dividend Yield: 5.66%
<ul>
<li>Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating with a price target of $45 on Sept. 16. This analyst has an accuracy rate of 70%.</li>
<li>Wells Fargo analyst Mohit Bansal maintained an Equal-Weight rating and raised the price target from $28 to $30 on July 31. This analyst has an accuracy rate of 78%.</li>
<li>Recent News: Pfizer recently presented positive data from Phase 2 study of Ponsegromab in Patients with cancer cachexia.</li>
<li>Benzinga Pro's real-time newsfeed alerted to<a href="https://pro.benzinga.com/dashboard"> latest PFE news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://pro.benzinga.com/dashboard"><img loading="lazy" decoding="async" width="906" height="835" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20052536/image-161.png" alt="" class="wp-image-557905" style="width:703px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20052536/image-161.png 906w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20052536/image-161-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20052536/image-161-768x708.png 768w" sizes="(max-width: 906px) 100vw, 906px" /></a></figure>
<h3 class="wp-block-heading">CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</h3>
<ul>
<li>Dividend Yield: 4.55%</li>
<li>RBC Capital analyst Ben Hendrix reiterated an Outperform rating with a price target of $68 on Sept. 4. This analyst has an accuracy rate of 74%</li>
<li>Barclays analyst Andrew Mok maintained an Equal-Weight rating and cut the price target from $65 to $63 on Aug. 8. This analyst has an accuracy rate of 79%.</li>
<li>Recent News: Wednesday, Oak Street Health, a subsidiary of CVS Health, agreed to settle for $60 million following allegations that it violated the False Claims Act.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://pro.benzinga.com/dashboard">trend in CVS stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://pro.benzinga.com/dashboard"><img loading="lazy" decoding="async" width="908" height="855" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20052607/image-162.png" alt="" class="wp-image-557908" style="width:653px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20052607/image-162.png 908w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20052607/image-162-300x282.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20052607/image-162-768x723.png 768w" sizes="(max-width: 908px) 100vw, 908px" /></a></figure>
<h3 class="wp-block-heading">Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)</h3>
<ul>
<li>Dividend Yield: 3.67%</li>
<li>RBC Capital analyst Brian Abrahams maintained a Sector Perform rating and raised the price target from $72 to $74 on Sept. 4. This analyst has an accuracy rate of 65%.</li>
<li>Needham analyst Joseph Stringer reiterated a Hold rating on Aug. 15. This analyst has an accuracy rate of 80%.</li>
<li>Recent News: Gilead Sciences, last week, revealed the results of an interim analysis from a second Phase 3 trial investigating the use of the company's twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://pro.benzinga.com/dashboard">breakout in GILD shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://pro.benzinga.com/dashboard"><img loading="lazy" decoding="async" width="891" height="841" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20052656/image-163.png" alt="" class="wp-image-557910" style="width:574px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20052656/image-163.png 891w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20052656/image-163-300x283.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20052656/image-163-768x725.png 768w" sizes="(max-width: 891px) 100vw, 891px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/09/40952252/nvidia-tesla-rally-as-dow-s-p-500-surge-to-fresh-highs-after-fed-cuts-rates-fear-index-remains-in-g">Nvidia, Tesla Rally As Dow, S&amp;P 500 Surge To Fresh Highs After Fed Cuts Rates: Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields

Cantor Fitzgerald analyst Olivia Brayer reiterates Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Neutral and maintains $70 price target.

Reiteration

Cantor Fitzgerald Reiterates Neutral on Gilead Sciences, Maintains $70 Price Target

Consider Buying Gilead To Benefit From Its Strong Outlook, Favorable Valuation

Barclays analyst Carter Gould maintained a Hold rating on Gilead Sciences (GILD – Research Report) on October 4 and set a price target of $84.00. T...

Barclays Sticks to Their Hold Rating for Gilead Sciences (GILD)

Gilead Sciences (GILD – Research Report) received a Buy rating and price target from Wells Fargo analyst Mohit Bansal today. The company's shares c...

Gilead Sciences (GILD) was upgraded to a Buy Rating at Wells Fargo

Gilead upgraded to overweight by Wells Fargo, PrEP launch cited

The healthcare sector can be a safe haven if volatility increases.

Biotech Stocks Poised For Another Big Move In Q4

Analyst Michael Yee from Jefferies maintained a Buy rating on Gilead Sciences (GILD – Research Report) and keeping the price target at $95.00. Mich...

Buy Rating Affirmed: Gilead's Breakthrough HIV Prevention and Promising Long-Acting Treatments

My Top 3 Large Cap Magic Formula Stocks For October 2024

ClearBridge Value Strategy Q3 2024 Commentary

Arcus a new overweight at Wells Fargo on potential of casdatifan in kidney cancer

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Accolade (ACCD – Research Report) and Gilead Scien...

Analysts Offer Insights on Healthcare Companies: Accolade (ACCD) and Gilead Sciences (GILD)

ACCD

AESI

ARKG

ATKR

BIIB

CMCSA

CSCO

CTSH

DELL

EADSF

EBAY

EXEL

EXPE

FOXA

FRFHF

ILMN

LULU

MRVL

MUSA

RCUS

SLGN

SSNC

SWKS

TMUS

VRSN

Press Releases

Gilead's Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA

Gilead Sciences to Present at Upcoming Investor Conferences

Gilead to Present New Trodelvy® Data at the IASLC 2024 World Conference on Lung Cancer

Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies

Gilead's Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial

Gilead Signs Royalty-Free Voluntary Licensing Agreements With Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countries

Hetero Signs Voluntary Licensing Agreement with Gilead to Transform Global HIV response, Expanding Access to Groundbreaking Lenacapavir to 120 high-incidence countries

Gilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference

Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024

Gilead Sciences to Release Third Quarter 2024 Financial Results on Wednesday, November 6, 2024

Comments

Gilead Sciences

Actualités

Dernières nouvelles pour Gilead Sciences (NASDAQ:GILD) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL